ATE386517T1 - Substituierte benzimidazole und ihre anwendung in der krebsbehandlung - Google Patents

Substituierte benzimidazole und ihre anwendung in der krebsbehandlung

Info

Publication number
ATE386517T1
ATE386517T1 AT02772370T AT02772370T ATE386517T1 AT E386517 T1 ATE386517 T1 AT E386517T1 AT 02772370 T AT02772370 T AT 02772370T AT 02772370 T AT02772370 T AT 02772370T AT E386517 T1 ATE386517 T1 AT E386517T1
Authority
AT
Austria
Prior art keywords
cancer treatment
substituted benzimidazoles
benzimidazoles
substituted
cancer
Prior art date
Application number
AT02772370T
Other languages
English (en)
Inventor
Francois Clerc
Francois Hamy
Isabelle Depaty
Odile Angouillant-Boniface
Stephanie Deprets
Chantal Carrez
Manfred Roesner
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE386517T1 publication Critical patent/ATE386517T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT02772370T 2001-09-26 2002-09-26 Substituierte benzimidazole und ihre anwendung in der krebsbehandlung ATE386517T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01402460A EP1298125A1 (de) 2001-09-26 2001-09-26 Substituierte Benzimidazolverbindungen und ihre Verwendung zur Behandlung von Krebs

Publications (1)

Publication Number Publication Date
ATE386517T1 true ATE386517T1 (de) 2008-03-15

Family

ID=8182891

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02772370T ATE386517T1 (de) 2001-09-26 2002-09-26 Substituierte benzimidazole und ihre anwendung in der krebsbehandlung

Country Status (35)

Country Link
US (1) US7041668B2 (de)
EP (2) EP1298125A1 (de)
JP (1) JP4510450B2 (de)
KR (1) KR100891439B1 (de)
CN (1) CN100346786C (de)
AR (1) AR037096A1 (de)
AT (1) ATE386517T1 (de)
AU (1) AU2002337151B2 (de)
BR (1) BR0212856A (de)
CA (1) CA2461622C (de)
CO (1) CO5570675A2 (de)
CY (1) CY1107953T1 (de)
DE (1) DE60225159T2 (de)
DK (1) DK1432417T3 (de)
EA (1) EA006802B1 (de)
ES (1) ES2301682T3 (de)
GT (1) GT200200190A (de)
HR (1) HRPK20040293B3 (de)
HU (1) HUP0401756A3 (de)
IL (1) IL161059A0 (de)
ME (1) MEP16808A (de)
MX (1) MXPA04002042A (de)
MY (1) MY135339A (de)
NO (1) NO327008B1 (de)
NZ (1) NZ531246A (de)
PA (1) PA8555501A1 (de)
PE (1) PE20030427A1 (de)
PL (1) PL369527A1 (de)
PT (1) PT1432417E (de)
PY (1) PY0223362A (de)
RS (1) RS50896B (de)
SI (1) SI1432417T1 (de)
UY (1) UY27452A1 (de)
WO (1) WO2003028721A2 (de)
ZA (1) ZA200401887B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011250847B2 (en) * 2003-06-23 2013-06-20 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20070208166A1 (en) * 2003-10-24 2007-09-06 Exelixis, Inc. Tao Kinase Modulators And Method Of Use
DE102004010207A1 (de) 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
FR2868421B1 (fr) * 2004-04-01 2008-08-01 Aventis Pharma Sa Nouveaux benzothiazoles et leur utilisation comme medicaments
EP1598348A1 (de) 2004-05-18 2005-11-23 Aventis Pharma Deutschland GmbH Pyridazinonderivate als CDK2-Inhibitoren
EP1836161B1 (de) 2004-12-22 2016-07-20 BHI Limited Partnership Verfahren und zusammensetzungen zur behandlung von amyloidassoziierten krankheiten
CN101300251B (zh) * 2005-09-06 2011-08-03 史密丝克莱恩比彻姆公司 作为plk抑制剂的苯并咪唑噻吩化合物
FR2891273B1 (fr) * 2005-09-27 2007-11-23 Aventis Pharma Sa NOUVEAUX DERIVES BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE NOTAMMENT COMME INHIBITEURS DE CMet
SI2089417T1 (sl) 2006-10-12 2015-04-30 Bhi Limited Partnership Metode, spojine, sestavki in vektorji za dostavo 3-amino-1-propansulfonske kisline
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
EP2212327A1 (de) * 2007-10-12 2010-08-04 Abbott Laboratories Kristalline form 1 von 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazol-4-carbonsäureamid
FR2922550B1 (fr) 2007-10-19 2009-11-27 Sanofi Aventis Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet
FR2941950B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941951B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941949B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941952B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
WO2011091152A1 (en) * 2010-01-22 2011-07-28 Pablo Gastaminza Inhibitors of hepatitis c virus infection
BR112015013105B1 (pt) 2012-12-05 2022-02-08 Alnylam Pharmaceuticals, Inc Agente de rnai de fita dupla capaz de inibir a expressão de pcsk9, seus usos, composição farmacêutica e método de inibição da expressão de pcsk9 em uma célula in vitro
EP3340994A1 (de) 2015-08-25 2018-07-04 Alnylam Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur behandlung einer mit dem proprotein-konvertase-subtilisin-kexin (pcsk9)-gen assoziierte störung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2441201C2 (de) * 1974-08-28 1986-08-07 Hoechst Ag, 6230 Frankfurt Anthelminthisch wirksame 2-Carbalkoxyamino-5(6)-phenyl-sulfonyloxy-benzimidazole und Verfahren zu ihrer Herstellung
DE2541752A1 (de) * 1975-09-19 1977-03-24 Hoechst Ag Anthelminthisch wirksame 2-carbalkoxyamino-5(6)-phenyl-sulfonyloxy- benzimidazole und verfahren zu ihrer herstellung
DE3247615A1 (de) * 1982-12-23 1984-07-05 Hoechst Ag, 6230 Frankfurt Substituierte phenylsulfonyloxybenzimidazolcarbaminate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB9900752D0 (en) * 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders

Also Published As

Publication number Publication date
YU21404A (sh) 2006-08-17
RS50896B (sr) 2010-08-31
HK1068551A1 (en) 2005-04-29
UY27452A1 (es) 2003-02-28
NZ531246A (en) 2006-06-30
AU2002337151B2 (en) 2007-04-26
JP4510450B2 (ja) 2010-07-21
EA006802B1 (ru) 2006-04-28
EP1432417A2 (de) 2004-06-30
HRP20040293A2 (en) 2005-06-30
HRPK20040293B3 (hr) 2007-06-30
NO327008B1 (no) 2009-04-06
CA2461622C (en) 2008-12-02
GT200200190A (es) 2003-11-11
MY135339A (en) 2008-03-31
HUP0401756A3 (en) 2005-06-28
CA2461622A1 (en) 2003-04-10
CO5570675A2 (es) 2005-10-31
EP1298125A1 (de) 2003-04-02
CY1107953T1 (el) 2013-09-04
EA200400475A1 (ru) 2004-08-26
KR100891439B1 (ko) 2009-04-03
PY0223362A (es) 2004-04-01
PT1432417E (pt) 2008-05-23
US7041668B2 (en) 2006-05-09
NO20041214L (no) 2004-06-24
DE60225159T2 (de) 2009-02-19
US20050014811A1 (en) 2005-01-20
HUP0401756A2 (hu) 2005-01-28
WO2003028721A3 (en) 2003-12-11
IL161059A0 (en) 2004-08-31
BR0212856A (pt) 2004-09-14
ZA200401887B (en) 2005-05-31
DK1432417T3 (da) 2008-06-16
WO2003028721A2 (en) 2003-04-10
PE20030427A1 (es) 2003-06-20
SI1432417T1 (sl) 2008-08-31
PL369527A1 (en) 2005-05-02
JP2005504112A (ja) 2005-02-10
ES2301682T3 (es) 2008-07-01
DE60225159D1 (de) 2008-04-03
CN1558761A (zh) 2004-12-29
CN100346786C (zh) 2007-11-07
EP1432417B1 (de) 2008-02-20
KR20040048904A (ko) 2004-06-10
MEP16808A (bs) 2010-06-10
PA8555501A1 (es) 2003-06-30
AR037096A1 (es) 2004-10-20
MXPA04002042A (es) 2004-06-07

Similar Documents

Publication Publication Date Title
DE60225159D1 (de) Substituierte benzimidazole und ihre anwendung in der krebsbehandlung
ATE318821T1 (de) Pyranoindazole und ihre verwendung in der glaukombehandlung
ATE432264T1 (de) Cycloalkylsubstituierte benzimidazole und ihre verwendung als parp inhibitoren
DE50009118D1 (de) Heterozyklisch substituierte benzimidazole, deren herstellung und anwendung
EE200500011A (et) Indasoolid, bensotiasoolid ja bensoisotiasoolid, nende valmistamine ning kasutamine
DE60107859D1 (de) Benzimidazolderivate, ihre herstellung und therapeutische verwendung
IS6656A (is) Útskiptar kínasólínafleiður og notkun þeirra sem hemla
PL377215A1 (pl) Pochodne benzimidazolu oraz ich zastosowanie w charakterze ligandów receptora waniloidowego
IS7926A (is) 4-útskipt bensímídasól og notkun þeirra sem magasýruseytishemla
DE60025747D1 (de) Neue benzimidazol derivate verwendbar als antiproliferative mittel
ATE259789T1 (de) Substituierte benzimidazole und ihre verwendung als parp inhibitoren
PL373484A1 (en) Vanilloid receptor ligands and their use in treatments
DE60132052D1 (de) Bohr- und Behandlungsflüssigkeiten
EP1681951A4 (de) Orthose-fussplatte und knöchel-fuss-orthose unter verwendung der orthose-fussplatte
DE60112791D1 (de) Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität
DE50110181D1 (de) Substituierte 2-anilino-benzimidazole und ihre verwendung als nhe-inhibitoren
IS8329A (is) Kínólínafleiður og notkun þeirra í meðferð
ATE359274T1 (de) Imidazol- und benzimidazol- caspase inhibitoren und deren verwendung
ATE437860T1 (de) 2-hydroxy-mutilin-carbamat derivate und ihre anwendung als antibakterielle mittel
IS6967A (is) Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
PL356784A1 (pl) Substancja do zastosowania w leczeniu łuszczycy
DE60319400D1 (de) Atemfähiges und mehrlagiges gewebe
PL377180A1 (pl) Zastosowanie izoflawonów i ich pochodnych w leczeniu mukopolisacharydoz
DE60215485D1 (de) Hydraulikpumpendüse und verwendungsverfahren
ATE312825T1 (de) N-alkoxyalkyl-substituierte benzimidazole und ihre verwendung als mittel gegen parasitäre protozoen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1432417

Country of ref document: EP